Aeglea raises $50M in IPO after slashing share price

John Carroll Austin, TC-based Aeglea BioTherapeutics raised $ 50 million in its IPO after pricing 5 million shares at $ 10 each, far below the range that it had set out for itself. FierceBiotech ...

Proteostasis and AveXis test the troubled IPO waters as biotech valuations wane

Damian Garde A pair of early-stage biotech companies has joined the thinning queue of drug developers trying to go public amid a painful market correction, angling to raise more than ...

UPDATED: Big investor to activists: J&J should break up, so please put on the heat

Tracy Staton Should Johnson & Johnson join the Big Pharma split-up club? One of its major shareholders thinks so, and it's pressing activist investors to join the cause. FiercePharma ...

Backed by Novartis and Orbimed, Adicet joins immunotherapy crowd with $51M round

John Carroll Adicet Bio has jumped out of stealth mode–more or less–with a $ 51 million A round and plans to combine two platform technologies into a next-gen approach ...

Anti-PD-1? Well, no, says Medivation as a partial hold forces a halt to ‘pivotal’ cancer study

John Carroll When Medivation bought out the rights to CureTech's pidilizumab, it trumpeted its entry into checkpoint inhibition with a drug that aimed right at PD-1, unleashing ...

Struggling XenoPort rumored to consider a sale

Damian Garde XenoPort, a month removed from deep job cuts, is looking to sell itself, according to Reuters, reaching out to potential acquirers after a string of R&D disappointments. FierceBiotech ...

Astellas is still struggling to close its $379M Ocata buyout

Damian Garde When Astellas signed a deal to acquire Ocata Therapeutics in November, it expected the company's shareholders to accept its $ 8.50-a-share offer within 20 days. But ...

NHS watchdog takes issue with Pfizer exec’s new role on foundation trust’s board

Tracy Staton A top Pfizer executive joined the board of a National Health Service Trust in England, triggering questions about potential conflicts of interest, an NHS-focused news service ...

Lilly and Incyte shoot for FDA approval with an oral RA drug

Damian Garde Partners Eli Lilly and Incyte filed an oral rheumatoid arthritis treatment for FDA approval, hoping to launch an agent that can steal market share from blockbuster injectables. FierceBiotech ...

Merck reaches $830M settlement in long-running Vioxx litigation

Emily Wasserman Merck is closing a chapter in its seemingly never-ending saga for its painkiller Vioxx, agreeing to pay more than $ 800 million to settle a lawsuit over the med years ...

FDA slaps down BioMarin’s Duchenne’s drug as rival nears a moment of truth

John Carroll After outlining its objections to BioMarin's application for its experimental Duchenne muscular dystrophy drug drisapersen in an internal review and hearing clear objections ...

For its next pare-down move, Pfizer weighs sale of Hospira pump business: Bloomberg

Emily Wasserman Pfizer has been contemplating a large-scale breakup for a while, with analysts expecting the company to split off its established drugs business once it integrates assets ...
Page 1 of 3512345...102030...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS